Success Metrics

Clinical Success Rate

100.0%

Based on 7 completed trials

Completion Rate

100%(7/7)

Active Trials

0(0%)

Results Posted

43%(3 trials)

Phase Distribution

Ph phase_1

57%

Ph phase_2

43%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

4(57.1%)

Phase 2Efficacy & side effects

3(42.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(7)

Detailed Status

Completed7

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 14 (57.1%)

Phase 23 (42.9%)

Trials by Status

completed7100%

Recent Activity

0 active trials

Showing 5 of 7

completedphase_2

Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA)

NCT00623779

completedphase_2

Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation

NCT00684307

completedphase_2

Clinical Trials (7)

Showing 7 of 7 trials

NCT00623779Phase 2

Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA)

Completed

NCT00684307Phase 2

Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation

Completed

NCT00645853Phase 2

Long-term Safety in Atrial Fibrillation Patients

Completed

NCT00812344Phase 1

Effect of Ketoconazole on Biliary Excretion of AZD0837

Completed

NCT00904800Phase 1

AZD0837 Extended Release (ER) Japan Study

Completed

NCT00878618Phase 1

Pharmacokinetics of Extended-Release Test- and Reference Formulations of AZD0837

Completed

NCT00812643Phase 1

Excretion of Radiolabelled AZD0837

Completed

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7